Danish biotech Genmab hit by ending of trial using key cancer drug


COPENHAGEN: Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug. Genmab said Janssen, a Johnson & Johnson business, had decided that the study of Darzalex plus atezolizumab, marketed by Roche as Tecentriq, in patients with previously treated non-small cell lung cancer would be ended.



from Biotech News